Please use this identifier to cite or link to this item:
|Title:||Corncob arabinoxylan for new materials|
|Abstract:||Limited data exist on the costs of care of patients with multiple sclerosis (MS) in low- to middle-income nations. The purpose of this study was to describe the economic burden associated with care of Mexican patients with relapsing-remitting MS in a representative sample of the largest institution of the Mexican public healthcare system. We analysed individual data of 492 patients (67 % women) with relapsing-remitting MS registered from January 2009 to February 2011 at the Mexican Social Security Institute. Direct costs were measured about the use of diagnostic tests, disease-modifying therapies (DMTs), symptoms control, medical consultations, relapses, intensive care and rehabilitation. Four groups were defined according to DMT alternatives: (1) interferon beta (IFN?)-1a, 6 million units (MU); (2) IFN?-1a, 12MU; (3) IFN?-1b, 8MU; and (4) glatiramer acetate. All patients received DMTs for at least 1 year. The most frequently used DMT was glatiramer acetate (45.5 %), followed by IFN?-1a 12MU (22.6 %), IFN?-1b 8MU (20.7 %), and IFN?-1a 6MU (11.2 %). The mean cost of a specialised medical consultation was 74.90 (US $107.00). A single relapse had a mean total cost of 2,505.97 (US $3,579.96). No differences were found in annualised relapse rates and costs of relapses according to DMT. However, a significant difference was observed in total annual costs according to treatment groups (glatiramer acetate being the most expensive), mainly due to differences in unitary costs of alternatives. From the public institutional perspective, when equipotent DMTs are used in patients with comparable characteristics, the costs of DMTs largely determine the total expenses associated with care of patients with relapsing-remitting MS in a middle-income country. " 2013 Belgian Neurological Society.",,,,,,"10.1007/s13760-013-0200-z",,,"http://hdl.handle.net/20.500.12104/40401","http://www.scopus.com/inward/record.url?eid=2-s2.0-84891647794&partnerID=40&md5=e91c85bf23b6b1d7624a3e6ea4d31f69",,,,,,"4",,"Acta Neurologica Belgica",,"415|
WOS",,,,,,"Neurosciences & Neurology; Costs of care; Glatiramer acetate; Healthcare; Interferon; Multiple sclerosis",,,,,,"Cost of care according to disease-modifying therapy in Mexicans with relapsing-remitting multiple sclerosis",,"Article" "44854","123456789/35008",,"Gonzalez-Perez, O., Neuroscience Laboratory, Psychology School, University of Colima, Avenue Universidad 333, 28040 Colima, COL, Mexico, Department of Neuroscience, University of Guadalajara, Sierra Mojada No. 950, 44340 Guadalajara, JAL, Mexico; García-Verdugo, J.M., Laboratorio de Morfologia Celular, Centro de Investigacion Principe Felipe, CIBERNED, 46031 Valencia, Spain, Department of Comparative Neurobiology, Instituto Cavanilles, University of Valencia, 46071 Valencia, Spain; Quinones-Hinojosa, A., Department of Neurosurgery, Johns Hopkins Bayview Medical Center, Baltimore, MD 21224, United States; Luquin, S., Department of Neuroscience, University of Guadalajara, Sierra Mojada No. 950, 44340 Guadalajara, JAL, Mexico; Gudino-Cabrera, G., Department of Cellular and Molecular Biology, University of Guadalajara, 45110 Zapopan, JAL, Mexico; Gonzalez-Castaneda, R.E., Department of Neuroscience, University of Guadalajara, Sierra Mojada No. 950, 44340 Guadalajara, JAL, Mexico",,"Gonzalez-Perez, O.
Gonzalez-Castaneda, R.E.",,"2012",,"[No abstract available]",,,,,,"10.1155/2012/378356",,,"http://hdl.handle.net/20.500.12104/43075","http://www.scopus.com/inward/record.url?eid=2-s2.0-84870185940&partnerID=40&md5=456982fb43e53c82a1aa317642bb8aaa
http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=prem&AN=23213339",,,,,,,,"Stem Cells International",,"378356",,,,"Scopus
MEDLINE",,,,,,,,,,,,"Neural stem cells in the adult brain: From benchside to clinic",,"Editorial" "42157","123456789/35008",,"Egüis, I., Chemical and Environmental Engineering Department, University of the Basque Country, Plaza Europa, 1, 20018 Donostia-San Sebastián, Spain; Stepan, A.M., Department of Chemical and Biological Engineering, Biopolymer Technology, Chalmers University of Technology, SE-412 96 Goteborg, Sweden, Wallenberg Wood Science Center, Goteborg, Sweden; Eceiza, A., Chemical and Environmental Engineering Department, University of the Basque Country, Plaza Europa, 1, 20018 Donostia-San Sebastián, Spain; Toriz, G., Department of Wood, Cellulose and Paper Research, University of Guadalajara, Guadalajara, Mexico, Wallenberg Wood Science Center, Goteborg, Sweden; Gatenholm, P., Department of Chemical and Biological Engineering, Biopolymer Technology, Chalmers University of Technology, SE-412 96 Goteborg, Sweden, Wallenberg Wood Science Center, Goteborg, Sweden; Labidi, J., Chemical and Environmental Engineering Department, University of the Basque Country, Plaza Europa, 1, 20018 Donostia-San Sebastián, Spain",,"Egues, I.
Labidi, J.",,"2014",,"Corncob agricultural waste was used as a source of arabinoxylan for preparation of films. Three arabinoxylan samples were prepared: crude extract (CCAX), purified by a washing step, and purified by bleaching CCAX. Films prepared with untreated CCAX were water soluble, yellowish in color and had poor mechanical properties. After the purification processes the Young's modulus increased from ?293 MPa to ?1400-1600 MPa, and strength was improved from ?9 MPa to around 53 MPa, while the strain at break was kept at ?8% both in untreated and purified CCAX. The contact angle was increased from ?21.3 to 67-74 after washing or bleaching CCAX. Acetylation of bleached CCAX showed the highest thermal resistance (325 C), had low Tg (125 C) and a high contact angle (80), and its films were stronger (strength ?67 MPa; Young's modulus ?2241 MPa) and more flexible (?13%). These characteristics make purified CCAX a suitable material to be used as a matrix for film applications." 2013 Elsevier Ltd. All rights reserved.
|Appears in Collections:||Producción científica UdeG|
Files in This Item:
There are no files associated with this item.
Items in RIUdeG are protected by copyright, with all rights reserved, unless otherwise indicated.